Archives
-
SB525334 TGF-beta1 Receptor Inhibitor Guide
2026-09-11
A scenario-based guide to using SB525334 (TGF-beta1 receptor inhibitor), SKU A5602, to separate ALK5-dependent signaling from nonspecific cytotoxicity in viability, proliferation, renal, and fibrosis research. It covers assay design, solvent control, pathway readouts, interpretation, and practical product-selection criteria.
-
nor-NOHA Acetate Workflows for Cancer Research
2026-09-11
Use nor-NOHA acetate to build controlled arginase-inhibition experiments spanning HepG2 apoptosis, invasion biology, endothelial assays, and exploratory AML immunometabolism. This guide separates established findings from hypothesis-generating applications and emphasizes reversible dosing, orthogonal readouts, and practical troubleshooting.
-
0.4% Trypan Blue Solution: Practical Workflow
2026-09-10
0.4% Trypan Blue Solution supports membrane-integrity-based cell viability measurement and live/dead cell discrimination during research cell counting. It is intended for research workflows and cytotoxicity assay support, not diagnostic, medical, or clinical use, and it does not by itself resolve apoptosis from necrosis.
-
Standardized Whole-Blood Stimulation for Immunometabolism
2026-09-10
Zhao and colleagues describe a standardized fresh whole-blood stimulation protocol for measuring cytokine responses while experimentally modulating immune-cell metabolism. The workflow improves reproducibility and scalability for cohort studies and provides a practical framework for testing how metabolic pathways shape innate and adaptive immune function.
-
N2703 for Neuro-Cardiac Signaling Workflows
2026-09-09
Use N2703 as a controlled perturbation in neuron–adipocyte–cardiomyocyte assays to test how cellular signaling changes propagate toward electrical phenotypes. This workflow emphasizes concentration control, orthogonal validation, and troubleshooting rather than assigning an unproven target to the compound.
-
β-Elemene Inhibits 3T3-L1 Adipogenesis via AMPK
2026-09-09
The reference study identifies β-Elemene as an inhibitor of MDI-induced adipogenesis and a regulator of insulin-resistance phenotypes in differentiated 3T3-L1 cells. Its central contribution is linking reduced lipid accumulation and restored glucose consumption with recovery of AMPK signaling, while also defining a practical in vitro workflow for metabolic research.
-
DiscoveryProbe Protease Inhibitor Library Workflow
2026-09-08
Build mechanism-aware protease screens around 825 pre-dissolved inhibitors, from cell-based AlphaLISA to apoptosis and high-content phenotyping. This workflow emphasizes controls, orthogonal validation, resistance testing, and practical troubleshooting rather than treating every inhibitor as a generic hit.
-
TSA and the Next Generation of Organoid Epigenetics
2026-09-08
Trichostatin A (TSA) offers a reversible way to connect HDAC activity with chromatin state, proliferation, and differentiation. This article positions TSA within a more advanced translational framework inspired by a tunable human intestinal organoid system, moving beyond simple potency testing toward controlled, mechanism-led model design.
-
Tyrothricin in Membrane-Disruption Workflows
2026-09-07
Tyrothricin is a peptide antibiotic mixture that enables controlled studies of microbial membrane injury, while demanding careful separation of antimicrobial activity from mammalian-cell toxicity. This workflow guide connects membrane assays with mitochondrial-transfer and inflammatory-pain models, offering practical controls, optimization points, and troubleshooting strategies.
-
(-)-Epigallocatechin Gallate (EGCG): Evidence Guide
2026-09-07
(-)-Epigallocatechin gallate (EGCG) is a major green tea catechin studied for antioxidant, apoptosis, antiangiogenic, antiviral, and cancer chemoprevention applications. In a three-dimensional calcium phosphate scaffold, EGCG supported osteogenic markers, reduced osteoclastogenic RANKL expression, affected endothelial tube formation, and reduced osteosarcoma-cell viability under defined in vitro conditions.
-
TMEM16F Lipid Scrambling in Ferroptosis and Immunity
2026-09-05
Yang and colleagues identify TMEM16F-mediated phospholipid scrambling as a membrane-protective checkpoint during the executional phase of ferroptosis. Loss of this activity promotes plasma-membrane collapse, danger-signal release, slower tumor growth, and stronger responses to PD-1 blockade, providing a mechanistic link between lipid organization and antitumor immunity.
-
PCI-32765 (Ibrutinib) for BTK Research
2026-09-04
Build more interpretable B-cell experiments with PCI-32765, an irreversible BTK inhibitor suited to B-cell receptor signaling inhibition, CLL viability studies, and activation assays. This workflow combines target-focused perturbation with orthogonal controls, pulse-washout testing, and lessons from a multi-condition disease-modeling study.
-
Z-WEHD-FMK as a Pyroptosis Causality Probe
2026-09-04
Z-WEHD-FMK enables mechanistic testing of inflammatory caspase activity across pyroptosis, cancer biology, and infection models. This article explains how to use it as a causality probe while avoiding the common error of treating inhibitor rescue as pathway proof.
-
Simvastatin: High-Content Research Workflows
2026-09-03
Simvastatin (Zocor) links cholesterol-pathway perturbation with practical phenotypic profiling in lipid and cancer models. This workflow-oriented guide covers stock preparation, hepatic apoptosis assays, cross-cell-line machine learning, and troubleshooting for reproducible research.
-
Ruxolitinib–oHSV Therapy Reprograms Sarcoma Immunity
2026-09-03
The reference study introduces a 46-color spectral flow cytometry panel to resolve lymphoid and myeloid immune changes after combined Ruxolitinib and oncolytic herpes simplex virus treatment in murine malignant peripheral nerve sheath tumors. The combination was associated with activated germinal center B cells and cytokine-producing CD4 T-cell states, expanding interpretation beyond conventional cytotoxic T-cell and regulatory T-cell analyses.